Global Cancer Biological Therapy Market, By Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Cytokine, Others), Route of Administration (Intravenous, Subcutaneous, Intramuscular, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Cancer Biological Therapy Market Analysis and Size
The global cancer biological therapy market is expected to witness significant growth during the forecast period. The growing number of cancer cases and the increasing number of special cancer treatment facilities worldwide are expected to help expand the global cancer biological therapy market. Several specialists in the cancer biological therapy market are focusing towards the utilization of nanotechnology to offer development therapy to patients. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global cancer biological therapy market in the forecast period 2022-2029. The expected CAGR of global cancer biological therapy market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 98 billion in 2021, and it would grow upto USD 181.39 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Biological therapy is cancer treatment that uses the body's immune system to fight against cancerous cells without affecting the healthy cells. The biological drug therapy such as monoclonal antibodies exerts their action by either hindering the cancer growth or rise cell death. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Cancer Biological Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Cytokine, Others), Route of Administration (Intravenous, Subcutaneous, Intramuscular, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Endo Pharmaceuticals plc (Ireland), Zydus Group (India), Bausch Health Companies Inc. (Canada)
|
|
Market Opportunities
|
|
Global Cancer Biological Therapy Market Dynamics
Drivers
- Increase in Cancer Cases
The rise in cancer cases globally boosts the global cancer biological therapy market in the forecast period As per the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with an estimated global death rate being 30,000 per year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women causing 1.59 million deaths in 2012. This boost the market growth.
- Rising Healthcare Awareness
Awareness among patients as well as healthcare providers about the incidence of cancer is on the rise. Patients and doctors are now more actively participating in learning about the therapies available for treating these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.
Opportunities
- Patent Expiration Encourages New Launches
The patent expiration of several previous companies can create enhanced opportunities for the new market players. The wide adoption of combination therapies is a major factor contributing to the growth of the cancer biological therapy market. Additionally, R&D fundings are an add-on to the market.
- Development of Diversified Treatments
Researchers in the cancer biological therapy market primarily focus on the use of nanotechnology to offer advanced treatment to patients. Nanotechnology has the utmost potential to help in the cancer diagnosis. Furthermore, protein engineering and materials science advances are expected to help medical professionals target cancer cells more precisely. This is anticipated to provide new hope to cancer patients.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global cancer biological therapy market over a forecast period.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
This global cancer biological therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cancer biological therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cancer Biological Therapy Market Scope
The global cancer biological therapy market is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Monoclonal Antibodies
- Vaccines
- Cancer Growth Blockers
- Cytokine
- Others
Route of Administration
- Intravenous
- Subcutaneous
- Intramuscular
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Cancer Biological Therapy Market Regional Analysis/Insights
The global cancer biological therapy market is analysed and market size insights and trends are provided by type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global cancer biological therapy market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the increase prevalence of cancer, high demand of biological therapies and advanced healthcare facilities.
North America dominates the market due to the increase awareness about the diseases and rapidly disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cancer Biological Therapy Market Share Analysis
The global cancer biological therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cancer biological therapy market
Key players operating in the global cancer biological therapy market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Endo Pharmaceuticals plc (Ireland)
- Zydus Group (India)
- Bausch Health Companies Inc. (Canada)
SKU-